GlassScriptPhysician profile
Juan C Paramo
NPI 1790715365
$2,993.30
in general payments reported to CMS, 2019-2025
27 companies · $15.48 in 2025
The $15.48 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $67.13 · 2021: $284 · 2022: $513 · 2023: $923 · 2024: $443 · 2025: $15.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990 · Travel and Lodging: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.07 |
| Travel and Lodging | $391.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $457.99 | 2023 | |
| Molli Surgical (US) INC | $343.01 | 2022-2023 | |
| Endomagnetics LTD | $309.74 | 2022-2024 | Magtrace, Magseed |
| Hologic Sales and Service, LLC | $287.77 | 2023-2024 | Trident Specimen Radiography System, Biozorb, Localizer |
| Genentech USA, INC. | $202.48 | 2019-2020 | |
| Sirtex Medical INC | $165.18 | 2021 | |
| Dilon Technologies, INC. | $147.60 | 2024 | Hemoblast Bellows |
| Myriad Genetic Laboratories, INC. | $124.59 | 2022 | |
| Leica Microsystems INC. | $119.11 | 2021 | |
| Covidien LP | $106.11 | 2019 | |
| C2dx, INC | $100.96 | 2023 | |
| Novartis Pharmaceuticals Corporation | $99.81 | 2019 | |
| Cardinal Health 414 LLC | $90.91 | 2019 | |
| Integra Lifesciences Corporation | $69.11 | 2022 | |
| Amgen INC. | $68.95 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $63.95 | 2019-2020 | |
| Abbvie INC. | $41.63 | 2019 | |
| Merck Sharp & Dohme LLC | $36.58 | 2019-2023 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $34.23 | 2019 | |
| Allergan, INC. | $31.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.03 | 2023 | Gattex |
| Pfizer INC. | $20.53 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.28 | 2019 | |
| Eusa Pharma (US) LLC | $16.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2025 | Xifaxan |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Paramo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.